Mandate

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén and Amanda Sandström (Capital Markets and Public M&A) as well as Arvid Weimers (Banking and Finance).

Related

Vinge advises Advania on the acquisition of Evolv Robotics

Vinge has advised Advania on the acquisition of Evolv Robotics, a fast-growing Icelandic software company specialising in digital workforce automation.
March 05, 2026

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026